We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sensyne Health Plc | SENS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.35 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.35 | 0.35 |
| Top Posts |
|---|
Posted at 27/10/2022 12:19 by paulsavannah Yes I noticed my portfolio list has deleted SENS and has been replaced with Arcturis Data Ltd in its place. Still a good sign if nothing else. |
Posted at 01/6/2022 09:54 by terminator101 Seriously mate, stopping access to NHS data has got nothing to do with delisting, but it's got everything to do with what sens actually do. Without that access, there is zero business and this company is totally worthless. That information surely needs an RNS to clarify as its a company killer. |
Posted at 15/10/2021 15:40 by rambutan2 Bigger data is better data:Dover, DE and Atlanta, GA. Oxford, U.K. October 15, 2021 : Sensyne Health plc (LSE: SENS) ("Sensyne"), the ethical Clinical AI company, and OMNY Health ("OMNY"), the largest US-based real world data network, today announced a strategic teaming relationship. The arrangement establishes a nimble framework under which Sensyne can contract for access to OMNY Health's platform of more than 22 million de-identified patient records across all therapeutic areas in support of Sensyne's data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research. By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies-and their health system partners-will have more opportunities to support important life sciences research. The OMNY data network complements Sensyne's existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK's National Health Service (NHS) trusts. With a data network that spans over 50,000 providers across 40 states, OMNY's data platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations. Sensyne will now have a new avenue to access an additional 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the combined total of de-identified patient data available for its research to over 44m patients. Derek Baird, President, North America, Sensyne Health said: "This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way. We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together." Mitesh Rao, MD, CEO, OMNY Health said: "OMNY Health embraces the opportunity to work with Sensyne Health's world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform. We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry. This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we've assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients." Sensyne is working with life science partners on different types of research projects across multiple disease areas. The actionable insights from OMNY's longitudinal patient data sets will help them with synthetic control arms, patient stratification, patient identification and selection, plus important late-phase clinical trial design, commercialisation, and health economic pricing decisions. |
Posted at 04/10/2021 09:34 by billy3 Well I’m sad to say that as of this morning, I am all out.I’ve been in this company for over 2 years and seen the highs and low. Made a decent amount on them but taken a hit this morning on current holdings as as most were bought back in higher. I’ll cover a few points which may assist other. In terms of the process, it took me 7 transactions and numerous attempts to sell my holdings. As it is the AIM I kept getting no quote back. (I use HL platform). All the while, the price drops and you can’t sell. I had a minimum price to sell and I was happy it stayed well above that. Most of my sells also showed as buys and above the displayed mid price so were incorrectly shown on level 2. Why have I sold ? I am both a trader and an investor. I’ve bought Sens and sold some to buy back 10 or 20p lower. Mainly an investor though. Sens is one of my only 2 physical share holdings as the rest of my cash is spread betting which I’ve done for over 20 years. So on a Perosnal level, Sens is a large part of my holdings and money I cannot afford to lose. Having seen the post about the times article (thank you )I considered the risk and it became too much for me. Sens is a fantastic company but the article made me realise what I actually knew, but hadn’t really thought through enough. On results day last week there were a number of things that bothered me. I kept thinking ‘cash burn’. As it always is with Sens, it is huge. Income dented it a bit but was likely just from Excalibur. First half this year below expectations ? Then it got to where the real gamble came in. The 25 possible contracts in the pipeline sounded great. Though it was buried at the bottom of the results. The company still think they can meet full year forecasts this current year, but the rub is, it’s contingent on getting those Contracts. The company profits is now hinged around sensight. So financially, that for me is too high risk and investment at the current price. In terms of the share price, it’s pretty much broken support and I see this heading back to 100p. Sentiment isn’t great at the moment for these type of companies after Covid. We’ve got a 6 month period now waiting to see what contracts come in and at least 6 months before we get a year end update. I don’t think many will hold in and wait. News on signed contracts will certainly help but we need to see profits. Looking at cash burn they need 20-25 mil income before they will make any money. I feel a little sadness being out after all this time. I think the next 6 months will be turbulent for the share price I also see yet another go at fundraising. I took part in the last one and took my full entitlement. I would love to know what Gatemore investment have to say on this matter as they are a large shareholder and activist investor. The above is all just my opinion and I hope my thinking assists others. I’d love to be back in as I still think the company has huge potential. But that will not likely be unless it’s under 100p and there is news of signed agreements for sensight with solid income. I’d be interested to hear others views as this BB seems to have thinned out over the months. To those still here, thanks for your contributions and keep them coming. |
Posted at 22/8/2021 20:27 by rambutan2 Oxford, U.K. 10 August 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the ethical Clinical AI company, today announces it has signed an agreement with Oxford University to conduct a multi-omics drug discovery research project in asthma.The three-year project will focus on identifying novel drug targets for patients with severe forms of asthma that do not respond to the current standard of care and where pre-existing treatments such as corticosteroids and biologics are less effective. Sensyne will apply its machine learning expertise and proprietary analytical tools to analyse complex genetic, phenotypic, and electronic patient record data sets for the Oxford University 'MultiOmics Project Study Genomics Asthma Project' ("MORSE"). The combination of three data sets will provide a platform for the identification of novel drug targets for the treatment of severe forms of asthma. The IP in any novel drug target identified by this research will be owned by Sensyne Health with a royalty payment back to Oxford University and the Oxford University Hospitals NHS Foundation Trust in line with the Strategic Research Agreements entered into between the parties and Sensyne in 2018. The research will aim to: -- Undertake whole genome sequencing ("WGS") of highly-phenotyped adult patients with severe forms of asthma from the Oxford Severe Asthma cohort. Data will be compared with controls to identify novel variations associated with specific highly defined asthma phenotypes -- Undertake detailed transcriptomic analysis of samples from airways of selected patients who have undergone WGS -- Develop a bioinformatic analysis pipeline which can integrate these datasets and provide proof of concept in identifying novel information on pathways and phenotypes Asthma is the most common chronic lung disease, affecting 350 million people worldwide and causing 400,000 deaths annually. Up to 10% of asthmatics have severe, treatment-refractory disease, constituting a significant unmet clinical need due to exacerbations, healthcare costs and mortality. Dr Timothy Hinks, Senior Research Fellow at the University of Oxford and Honorary NHS Consultant at the John Radcliffe Hospital , said: "As a clinician caring for people with severe and difficult-to-treat asthma I'm hugely excited about this collaboration. Asthma affects 1 in 12 adults in UK and severe forms of asthma has a major impact on people's lives with time off school and work, and hospital admissions. We still don't understand the causes of asthma, because in the past the scientific tools just didn't exist. Now we're at a point in history that we can use tiny samples from the airways of volunteers and study individual cells in incredible detail measuring how each gene is controlled, one cell at a time. As a scientist I'm optimistic this is going to bring about really significant new insights into the mechanisms that drive asthma, so we can develop some new treatments for this, the world's most common long-term lung condition. "This project is only made possible through a ground-breaking partnership between the University of Oxford, Sensyne Health and Oxford University Hospitals NHS Foundation Trust, sharing our resources and expertise to tackle a common problem." Chas Bountra Pro-Vice Chancellor for Innovation and Professor of Translational Medicine at the University of Oxford, said: "Partnering with industry is crucial for accelerating the life-changing, world-class research we do here at the University of Oxford. We are pleased to be working with Sensyne Health on this important project which will enable our scientists to look for breakthrough drug discoveries to combat respiratory disease." Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "We are delighted to be working with such world-class research partners on our first project to apply Sensyne's deep expertise in AI to the discovery of novel asthma drugs. AI enabled drug discovery is growing fast and Sensyne is well placed to apply its expertise to build leadership in this field." |
Posted at 01/6/2021 08:01 by billy3 WoooooooooHoooooo :-)‘Significant commercial’ and ‘national̵ Read back everything said before and this was where it was heading. Adopted by the DHSC and the ONLY product of its type. Sensyne Health PLC MagnifEye Production Contract with UK DHSC 01/06/2021 7:00am UK Regulatory (RNS & others) Sensyne Health (LSE:SENS) Intraday Stock Chart Tuesday 1 June 2021 Click Here for more Sensyne Health Charts. TIDMSENS RNS Number : 3067A Sensyne Health PLC 01 June 2021 MagnifEye Production Contract with the UK's Department of Health & Social Care Oxford, U.K. 01 June 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI technology company, today announces it has signed a production contract with the UK's Department of Health & Social Care (DHSC) to use Sensyne's MagnifEye AI technology for reading COVID-19 lateral flow diagnostic tests as part of the UK government's asymptomatic testing programme. The scope of this contract with DHSC is for a phased national roll-out over a three-month period in care homes, GP practices and selected private sector organisations with large workforces. Revenues will be shared with Excalibur Health Systems under the terms of the exclusive agreement between the two companies. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "This is a significant commercial milestone in Sensyne's development and underlines the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Department of Health & Social Care to support the UK's national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic." |
Posted at 27/5/2021 07:40 by billy3 Great update. Plenty of progress and revenue at last.Let’s see where the share price goes and hopefully some good press coverage. .................... Sensyne Health PLC Trading Update 27/05/2021 7:00am UK Regulatory (RNS & others) Sensyne Health (LSE:SENS) Intraday Stock Chart Thursday 27 May 2021 Click Here for more Sensyne Health Charts. TIDMSENS RNS Number : 0094A Sensyne Health PLC 27 May 2021 Sensyne Health Trading Update FY2021 trading performance ahead of market expectations Real world patient database and revenues rapidly growing Sensyne poised for accelerated international growth Oxford, U.K. 27 May 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the Clinical AI company, today announces an update on trading for the financial year ended 30 April 2021 ("FY 2021"), and an outlook statement. UPDATE ON TRADING -- Robust financial performance: FY 2021 unaudited revenues of at least GBP9.0 million (FY 2020: GBP2.1 million audited). -- Strong revenue growth driven by contracts with life sciences companies, with recognition of the majority of the GBP4.8 million minimum revenues from MagnifEye AI technology contract with Excalibur Health Services ("Excalibur"). -- Cash and cash equivalents were GBP23.6 million (unaudited) and excludes receipt of majority of minimum revenue payments from the Excalibur contract (FY 2020: GBP31.7 million audited). -- Fast growth of real world patient database: Acceleration in the growth of Sensyne's de-identified and anonymised real world patient database with access to total of 18.2 million unique records from the UK and the US. -- Access to c.8.5 million patient records in the UK, a three-fold increase during the financial year, following the signing of six new strategic research agreements ("SRAs") with NHS Trusts; provides coverage of c.13% of the UK population and a significant step towards the target of c.20%. -- In May 2021, the Company signed its first two US SRAs with leading healthcare providers St Luke's University Health Network, serving Pennsylvania and New Jersey, and Colorado Center for Personalised Medicine, providing access to 9.8 million patient records in the US. -- Sensyne now has one of the world's fastest growing longitudinal patient datasets, that includes the detailed phenotypic and genomic data needed for life sciences research. -- Life Science commercial agreements: Momentum continues in discovery sciences with new agreements announced with Alexion and Bristol Myers Squibb, and agreement signed with Excalibur Health for AI based diagnostics. Significant opportunity and good traction seen within business development pipeline including ongoing discussions with existing and new clients across the global pharmaceutical and diagnostic industries. -- Phesi collaboration: First commercial agreement as part of strategic collaboration with Phesi Inc., a clinical data specialist, signed with leading pharmaceutical company in May 2021. Additional commercial agreements for clinical trial optimisation expected during the current financial year. -- SENSIGHT Platform: Development of SENSIGHT platform to support rapid interrogation of the real world patient database and industrialisation of our offering to life science companies is on track for launch by mid-2021. -- Diagnostics: Development and launch of MagnifEye (TM) , an AI diagnostic lateral flow test reader during the year. Exclusive licensing and collaboration agreement for lateral flow testing applications secured with Excalibur generating minimum revenues of GBP4.8 million. Additional commercial opportunities for MagnifEye being pursued in the UK and internationally. -- SENSE Platform: Development of the SENSE healthcare platform building a suite of advanced AI enabled tools for use by healthcare systems and the life science industry. Access to recently expanded real world patient datasets and specialist datasets expected to broaden this portfolio of AI enabled software tools. -- Regulatory milestones: . UK MHRA emergency use derogation for MagnifEye received in May 2021. SYNE-COV clinical algorithm for assessing risk for COVID-19 patients admitted to hospital achieved UKCA status in February 2021 and submission to the US Food and Drug Administration of SYNE-GDm in May 2021. SYNE-GDm was submitted for approval under the Medical Device Regulation in August 2020 and a decision is expected soon. -- GDm-Health solution : Patient remote monitoring software for gestational diabetes now used by 56 NHS Trusts helped care for 28,338 pregnancies since launch in the UK. US launch of GDm in partnership with Cognizant in December 2020; uptake has been slower than expected due to impact of Covid-19 pandemic on US healthcare systems and competitive market environment. Other partnership opportunities being explored to support uptake of this software solution in the US market. Accelerating patient data strategy With the signing of two US SRAs recently building on our rapidly growing UK datasets, Sensyne Health is now accelerating its strategy to be a global leader in clinical AI with one of the largest and fastest-growing sets of ethical, de-identified and anonymised real world patient data. Sensyne now has access to a total of 18.2 million unique records from in UK and the US. Sensyne intends to continue to scale its dataset in a highly strategic manner to enhance its provision of high-quality longitudinal health data within the highest quality ethical framework exclusively focused on delivering improved patient care and accelerating medical research. New health care partners are expected to bring geographically diverse data in key therapeutic areas including cardiovascular, oncology and rare diseases. Different data types, including additional deep phenotypic, imaging and genomic data are expected to further enrich the database. In line with its previously announced strategy, Sensyne's focus will be on adding to its strong relationships in the UK and US, followed by expansion into Europe and Asia Pacific to support demand from existing and potential new life sciences customers. The Company currently has a pipeline of growing SRA opportunities under active discussion with healthcare systems to access a further c.40 million unique patient records in the UK and US alone reinforcing that Sensyne is seen as a partner of choice for healthcare systems. As the recent US agreements show, international SRAs are structured to place a greater emphasis on the future royalty opportunity rather than other economic parameters and allow Sensyne to continue to scale its access to global health data sustainably. Sensyne seeks to become a leader in the field by building an ethically-sourced real world dataset of c.100 million patient records by the end of 2024, representative of the patient populations in the key markets of interest to the life sciences industry. OUTLOOK Sensyne's robust financial performance, continued momentum with life sciences and the scale of the opportunities presented to it provides confidence in the future performance of the Company. Sensyne's rapidly growing patient databases and world-class expertise in clinical AI provide the foundation for substantial revenue growth and the potential to achieve global scale. The Company anticipates this revenue growth to be driven by life sciences in the near term, taking a flexible approach to the overall mix and to perform in line with its expectations for FY2022 total revenue. The Company continues to explore strategic opportunities, including acquisitions, that can leverage this strong organic growth and create additional shareholder value. Lord (Paul) Drayson PhD FREng, Chief Executive Officer of Sensyne Health , commented: "Covid-19 has accelerated the demand for deeply curated real world patient data and AI analytical tools to inform effective decision making in the delivery of patient care and the efficient development of new medicines. Sensyne Health's partnership model for the ethical use of patient data, in partnership with the NHS and US healthcare providers, has enabled it to build a leadership position in clinical AI that is reflected in our robust growth in data and revenues. The Company is now well placed to capitalise on this growth to become the global leader in the ethical application of clinical AI to patient data." |
Posted at 24/5/2021 21:36 by rambutan2 Deserves a full posting imho:Oxford, U.K, and Dover, Delaware, USA 24 May 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI company, today announces that it has signed its second Strategic Research Agreement ("SRA") in the U.S. with the Colorado Center for Personalized Medicine ("CCPM"), a partnership between non-profit health system UCHealth and the University of Colorado Anschutz Medical Campus The agreement will enable the ethical application of clinical AI research to improve patient care and accelerate medical research. This is in line with Sensyne's strategy of building a world-leading health data platform with industrial scale and robust patient data protection. The uptake of Sensyne's model in the U.S. demonstrates growing appetite for more advanced ethical data sourcing supported by patient information protection. The CCPM houses one of largest health data warehouses in the United States and has been a pioneer in driving large-scale personalized medicine and return of clinically actionable results through a research biobank, integrating personalized genomic information with clinical data. CCPM's significant advancements in making pharmacogenomics a standard of care are already providing benefits, and with plans to expand the provision of personalized healthcare, patients will soon have access to more clinically-actionabl The CCPM dataset covers 7.3 million de-identified and anonymised patients, including anonymised patient records from a UCHealth population of approximately 2.4 million active patients and a biobank of >180,000 research participants for which clinical genetic test results are being generated. UCHealth cares for patients through its network of 12 acute-care full-service hospitals and hundreds of clinic locations across Colorado, southern Wyoming and western Nebraska. Consistent with Sensyne's approach with all of its Strategic Research Agreements, research will be undertaken to the highest standards of information governance and data security and in accordance with The Health Insurance Portability and Accountability Act (HIPAA), the U.S. data protection legislation that protects sensitive patient information. All data supplied to Sensyne for research will be de-identified by CCPM beforehand and will remain in the U.S., and the provision of the data will operate under an agreed set of data processing procedures. Under the terms of the agreement, should the medical research undertaken by Sensyne using CCPM's data lead to medical discoveries commercialised by Sensyne, CCPM will share a proportion of Sensyne's revenues generated from that research. The agreement quickly follows Sensyne's first U.S. SRA announced on 21 May 2021 with St. Luke's University Health Network, a leading U.S. health system serving patients in Pennsylvania and New Jersey. These new US partners follow 11 National Health Service ( NHS) Trusts in the U.K., covering more than 13% of the U.K. population, which have partnered with Sensyne sharing anonymised clinical datasets to enable the discovery of new treatments, increase disease understanding, and advance clinical trial design. Kathleen Barnes, PhD, University of Colorado School of Medicine Professor and Director of CCPM , said: "This collaboration will take an already notable program at the CCPM and expand the depth and breadth of its capabilities, allowing us to give more back to patients everywhere through our collaborations. Our partnership with Sensyne Health will lead to an optimization of patient care, using personalized results to better inform research, clinical decision making, and potentially leading to new ways of diagnosing, preventing and treating illnesses." Lord (Paul) Drayson, PhD, CEO of Sensyne Health, said: " This agreement with Colorado Center for Personalized Medicine, covering both genomic and electronic health record data , will enable us to undertake research aimed at a deeper understanding of disease, and to accelerate the development of novel medicines in collaboration with our pharmaceutical partners. I'm delighted to be working with CCPM and excited about the capability that our growing international data collaborative now offers to the global life sciences research community." |
Posted at 13/11/2020 16:04 by billy3 Sensyne Health PLC13 November 2020 Sensyne Health appoints President, North America, to lead US expansion Oxford, U.K. 13 November 2020 : Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that it has appointed Derek Baird to its senior management team as President, North America. Derek will join Sensyne on 01 December 2020 and will focus on driving the commercial development of the Company's North American operations, building Sensyne's presence in the US and recruiting a US-based team. Derek joins Sensyne from AVIA, a digital transformation partner for health systems and payers, where he served as Senior Vice President, Growth. Prior to joining AVIA Derek was a Senior Vice President at healthcare software company Health Language (acquired by Wolters Kluwer Health), and has held senior product and marketing roles at Zynx Health and ambulatory electronic health records provider Practice Partner. Derek is a US national and will be based in the US. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "I'm delighted that Derek is joining the Sensyne team. His extensive experience, combined with a deep knowledge of US healthcare technology and US health systems, will be invaluable as we further capitalise on what we have already achieved in the UK by driving forward our expansion into the US and building a transatlantic business." Derek Baird, said: "I've been impressed with the progress that Sensyne has already made in the UK in such a short space of time. It is clear the value that Sensyne delivers in the UK is equally applicable to US heathcare systems and life sciences companies. I'm excited to bring the Sensyne vision and unique business model to the US market." |
Posted at 30/9/2020 14:48 by billy3 RNS Number : 6245ASensyne Health PLC 30 September 2020 Sensyne Health announces collaboration with the University of Oxford to provide software for remote symptom data collection and analytics for a Phase II clinical trial in care homes of adalimumab to prevent respiratory failure due to COVID-19 Highlights : · Sensyne's software for remote symptom data collection and analytics will support researchers in academia and the pharmaceutical industry to undertake clinical trials during the pandemic, particularly within the community environment · Collaboration with the University of Oxford for the AVID-CC Phase II clinical trial in care homes of the anti-TNF drug adalimumab funded by the Wellcome Trust · Further agreements to use Sensyne's capabilities in other clinical trials are in advanced discussions Oxford, U.K. 30 September 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces a collaboration with the University of Oxford in which Sensyne will provide software for remote data collection and analytics for the AVID-CC Phase II clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to COVID-19. The trial is funded by the COVID-19 Therapeutics Accelerator, an initiative set up by the Wellcome Trust, the Bill and Melinda Gates Foundation and Mastercard, with support from an array of public and philanthropic donors. The purpose of the trial is to assess the effectiveness of Adalimumab in preventing progression to respiratory failure or death due to COVID-19 infection. A particular feature of this trial, supported by Sensyne's software, is the remote collection of data on symptoms, vital signs and activities of daily living from clinical trial subjects in care homes, followed by a phase of exploratory data analysis using Sensyne's machine learning algorithms. The software is based on Sensyne's CVm-Health ™ software application for tracking COVID-19 symptoms launched earlier this year. The use of CVm-Health will allow clinical trial participants in care homes to record their symptoms and vital signs and enable trial investigators to access such data remotely. The 'Good Neighbour' aspect of CVm-Health, whereby a carer, with consent, can enter data on behalf of an individual, is an important feature that facilitates clinical trials in the community care environment. Under the trial protocol, and with the consent of participants, anonymised data recorded by the application during the trial will be analysed using machine learning algorithms developed by Sensyne. Sensyne is in advanced discussions for the use of its remote symptom and vital sign data collection software and analytics expertise by other clinical researchers seeking to undertake drug trials during the COVID-19 pandemic, particularly trials within community settings such as care homes. Further announcements will be made as such discussions reach agreement. Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "Sensyne is at the forefront of developing advanced remote monitoring software and clinical AI tools that enable clinical research to be undertaken during the new circumstances caused by the COVID-19 pandemic. We are delighted to be working with the University of Oxford on this important new trial of Adalimumab , pioneering new clinical research techniques in the community environment." Professor Duncan Richards FRCP, Climax Professor of Clinical Therapeutics and Director of the Oxford Clinical Trials Research Unit (OCTRU), formerly Head of Clinical Pharmacology and Experimental Medicine for GSK (until 2019), who is the Chief Investigator for the AVID-CC trial , said: " We have been impressed by Sensyne Health's digital health and clinical AI capabilities. We are excited by the opportunity that that flexible electronic diaries for remote data collection and analytics, such as CVm-Health for patients and carers to contribute to information collected in clinical trials. This pandemic has highlighted the need to re-examine the ways in which we collect data. We are delighted to be working with Sensyne and are excited by the potential for unique insights that may come from exploratory analyses of the anonymised clinical trial data using their proprietary machine learning algorithms." -ENDS- |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
